Forward-Looking Statements 2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Ac
Thursday, November 9, 2023 1 min read
Key Takeaway: Tailor dosing schedule to patient needs Manage the disease with different, complementary MOAs Potentially treat a chronic disease with both short- and long-acting drugs Optimize patient visit and flow EYP-1901 May Provide Greater Flexibility in Managing Patients 14
Full Press Release Details
Tailor dosing schedule to patient needs Manage the disease with different, complementary MOAs Potentially treat a chronic disease with both short- and long-acting drugs Optimize patient visit and flow EYP-1901 May Provide Greater Flexibility in Managing Patients 14